286 related articles for article (PubMed ID: 15711909)
1. GH receptor antagonist: mechanism of action and clinical utility.
Surya SK; Barkan AL
Rev Endocr Metab Disord; 2005 Jan; 6(1):5-13. PubMed ID: 15711909
[TBL] [Abstract][Full Text] [Related]
2. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
[TBL] [Abstract][Full Text] [Related]
3. Growth hormone receptor antagonists.
van der Lely AJ; Kopchick JJ
Neuroendocrinology; 2006; 83(3-4):264-8. PubMed ID: 17047392
[TBL] [Abstract][Full Text] [Related]
4. [Therapeutic management of acromegaly].
Metzner C; Hadziselimovic S; Grafe I; Nawroth P; Kasperk C
Med Klin (Munich); 2006 Jan; 101(1):15-23. PubMed ID: 16418810
[TBL] [Abstract][Full Text] [Related]
5. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs.
Herman-Bonert VS; Zib K; Scarlett JA; Melmed S
J Clin Endocrinol Metab; 2000 Aug; 85(8):2958-61. PubMed ID: 10946911
[TBL] [Abstract][Full Text] [Related]
6. Pegvisomant: current and potential novel therapeutic applications.
Thankamony GN; Dunger DB; Acerini CL
Expert Opin Biol Ther; 2009 Dec; 9(12):1553-63. PubMed ID: 19916734
[TBL] [Abstract][Full Text] [Related]
7. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
[TBL] [Abstract][Full Text] [Related]
8. Growth hormone receptor antagonists.
Kohn DT; Kopchick JJ
Minerva Endocrinol; 2002 Dec; 27(4):287-98. PubMed ID: 12511851
[TBL] [Abstract][Full Text] [Related]
9. Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly.
Drake WM; Parkinson C; Besser GM; Trainer PJ
Trends Endocrinol Metab; 2001 Nov; 12(9):408-13. PubMed ID: 11595543
[TBL] [Abstract][Full Text] [Related]
10. Medical progress: Acromegaly.
Melmed S
N Engl J Med; 2006 Dec; 355(24):2558-73. PubMed ID: 17167139
[No Abstract] [Full Text] [Related]
11. Primary medical therapy for acromegaly.
Sheppard MC
Clin Endocrinol (Oxf); 2003 Apr; 58(4):387-99. PubMed ID: 12641619
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin analogs in medical treatment of acromegaly.
Racine MS; Barkan AL
Endocrine; 2003 Apr; 20(3):271-8. PubMed ID: 12721507
[TBL] [Abstract][Full Text] [Related]
13. Experience with pegvisomant in the treatment of acromegaly.
Drake WM
Growth Horm IGF Res; 2001 Jun; 11 Suppl A():S111-4. PubMed ID: 11527081
[TBL] [Abstract][Full Text] [Related]
14. The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues.
De Martino MC; Auriemma RS; Brevetti G; Vitale G; Schiano V; Galdiero M; Grasso L; Lombardi G; Colao A; Pivonello R
J Endocrinol Invest; 2010 Oct; 33(9):663-70. PubMed ID: 20595800
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
[TBL] [Abstract][Full Text] [Related]
16. Plasma Agouti-Related Protein Levels in Acromegaly and Effects of Surgical or Pegvisomant Therapy.
Freda PU; Reyes-Vidal C; Jin Z; Pugh M; Panigrahi SK; Bruce JN; Wardlaw SL
J Clin Endocrinol Metab; 2019 Nov; 104(11):5453-5461. PubMed ID: 31361303
[TBL] [Abstract][Full Text] [Related]
17. New perspectives in the medical treatment of acromegaly.
Colao A; Pivonello R; Auriemma RS; Galdiero M; Guerra E; Milone F; De Leo M; Lombardi G
J Endocrinol Invest; 2005; 28(11 Suppl International):58-66. PubMed ID: 16625847
[TBL] [Abstract][Full Text] [Related]
18. Pegvisomant and improvement of quality of life in acromegalic patients.
Neggers SJ; van der Lely AJ
Horm Res Paediatr; 2011; 76 Suppl 1():102-5. PubMed ID: 21778759
[TBL] [Abstract][Full Text] [Related]
19. Pegvisomant: a growth hormone receptor antagonist for the treatment of acromegaly.
Parkinson C; Trainer PJ
Growth Horm IGF Res; 2000 Apr; 10 Suppl B():S119-23. PubMed ID: 10984267
[TBL] [Abstract][Full Text] [Related]
20. [Advances in the treatment of acromegaly].
Krysiak R; Okopień B; Marek B
Pol Merkur Lekarski; 2008 Jan; 24(139):59-65. PubMed ID: 18634256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]